

**Table 3.** Thyroid function tests of five patients with Graves' disease after alemtuzumab therapy

| <b>Value<br/>(Unit)</b> | <b>TSH<br/>(mU/l)</b> | <b>fT3<br/>(pmol/l)</b> | <b>fT4<br/>(pmol/l)</b> | <b>TSHR-Ab<br/>(U/l)</b> | <b>TPO-Ab<br/>(U/ml)</b> | <b>Tg-Ab<br/>(U/ml)</b> |
|-------------------------|-----------------------|-------------------------|-------------------------|--------------------------|--------------------------|-------------------------|
| 1                       | <0.01                 | 38                      | 85                      | 8                        | >3000                    | 89                      |
| 2                       | <0.01                 | 32                      | 65                      | 12                       | 93                       | 89                      |
| 3                       | <0.01                 | 25                      | 44                      | 39                       | 38                       | 73                      |
| 4                       | <0.01                 | >50                     | >100                    | 22                       | >3000                    | 30                      |
| 5                       | <0.01                 | 7.8                     | 26                      | 3                        | 489                      | 962                     |
| Reference range         | 0.3-4.2               | 2.8-7.1                 | 12-22                   | <1                       | <60                      | <60                     |

TSH: thyroid-stimulating hormone, fT3: free triiodothyronine, fT4: free thyroxine, TSHR-Ab: antibodies against TSH receptor, TPO-Ab: antibodies against thyreoidaseperoxidase, Tg-Ab: antibodies against thyroglobulin.